All posts by: Michael Zand

About Michael Zand

Sangamo and Pfizer to Collaborate on Developing Gene Therapies for ALS – ALS News Today

Continue reading

2018-01-05 NEWS

ALS News Today

Sangamo and Pfizer to Collaborate on Developing Gene Therapies for ALS
ALS News Today
Sangamo Therapeutics and Pfizer will work together on gene therapies they hope will overcome mutations that cause ALS and frontotemporal lobar degeneration. Gene therapy works by delivering a healthy copy of a malfunctioning gene to a patient. The
Pfizer and Sangamo Partner on Gene Therapy for Lou Gehrig’s DiseaseBioPharm International
Pfizer buys into Sangamo’s motor neuron disease gene therapyPMLiVE

all 3 news articles »

Continue reading

2018-01-05 NEWS

FierceBiotech

Johnson & Johnson pens Alzheimer’s gene therapy pact
FierceBiotech
The workaround being pursued by J&J is underpinned by AAV research performed by Jim Wilson, M.D., Ph.D. and others at the university’s gene therapy program. Wilson and his collaborators have been working to improve AAVs for more than two decades

Continue reading

2018-01-05 NEWS

Xconomy

Bio Roundup: Trump, Gottlieb, Gene Therapy Prices, IPO Hopes & More
Xconomy
Welcome to the new year. What will it bring? Hopefully a lot less hatred, greed, stupidity, and angst than 2017. But we’re not holding our breath. We emerged from the winter break pondering several of the year’s burning biopharma questions, including